INDIANAPOLIS Roche has announced plans to invest up to $550 million in its Diagnostics facility in Indianapolis by 2030.

According to a release from the company, this expansion will position the site as a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems.

The investment aims to create hundreds of jobs and enhance production capabilities in the United States.

With more than 38 million Americans living with diabetes, the company says increased access to effective diabetes management tools is essential.

Roche's Indianapolis site serves as the North American headquarters for its Diagnostics division, and it plays a critical role in the company's global operations.

The facility currently produces about 5.2 billion Accu-Chek diabetes test strips each yea

See Full Page